XTL Biopharmaceuticals announces extraordinary shareholder meeting

• XTL Biopharmaceuticals scheduled an extraordinary general meeting in Tel Aviv on June 22, 2026.
• Shareholders will vote on a deal to acquire 80% to 100% of Psyga Bio, with consideration to Psyga shareholders in XTL ADSs or warrants, including additional milestone-based issuances.
• Agenda includes a conditional private placement raising up to USD 1.5 million from multiple investors, including Alexander Rabinovitch, with ADSs and Series A and Series B warrants.
• Meeting also seeks approval to increase authorized share capital by 2,900,000,000 shares to 5,800,000,000 shares, alongside appointment of Barzily & Co. C.P.A as independent auditor for year ended Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-057942), on May 15, 2026, and is solely responsible for the information contained therein.